If you’ve come to see me about cataract surgery or refractive lens exchange in the past, chances are we’ve talked about trifocal lenses — and specifically the PanOptix. It’s been the lens I’ve most recommended for patients wanting genuine independence from glasses, and for good reason. The clinical data supporting it has been excellent.
So when Alcon released the PanOptix Pro, I’ll admit I looked at it with a degree of healthy scepticism. Upgrades to a platform that’s already performing well can sometimes be more marketing than medicine. But after reviewing the data and seeing the results in my own patients, I’m genuinely impressed — and I think this lens represents a meaningful step forward, not just a rebrand.
Here’s what I think you need to know.
What's actually new about the PanOptix Pro?
The PanOptix Pro builds on the original PanOptix trifocal platform but introduces Alcon’s new Enhanced Precision Optics — a refinement to the diffractive ring design that reduces the light scatter responsible for the haloes and starbursts that some patients notice after trifocal IOL implantation.
The three focal points remain the same — distance (6 metres), intermediate (60–80 cm, ideal for screens and dashboards), and near (40 cm for reading) — but the light distribution between those focal points has been optimised. The practical result is improved contrast sensitivity and a smoother transition between focal distances, which matters most in low-light and night driving situations.
The lens also features an updated surface treatment that reduces posterior capsule opacification — the ‘secondary cataract’ that affects a meaningful proportion of patients in the years after surgery and requires a YAG laser in the rooms to fix. Any reduction in that rate is a genuine quality of life improvement for patients.
The improvement I notice most in my patients is the reduction in the early halo complaints. With the original PanOptix, I'd typically have a conversation at the six-week review about settling time. With the Pro, that conversation is happening less often.
What the clinical data shows
The PanOptix Pro FDA clinical study (P200038) provides the most robust independent dataset we have for this platform. The results across spectacle independence, visual acuity at all distances, and patient satisfaction are frankly exceptional for any surgical procedure.
The ‘very bothersome’ rate for visual side effects tells an equally reassuring story — haloes troubled fewer than 1.4% of patients significantly, starbursts around 2.6%, and glare just 0.8%. These are real side effects, and I never minimise them in my consultations. But the numbers put them in perspective: fewer than three people in a hundred find them genuinely troubling long-term.
In terms of uncorrected visual acuity, approximately 96% of patients achieved 20/40 or better at distance and intermediate without glasses, and around 90% achieved J3 or better at near. For a lens replacing one that almost certainly required glasses at all distances, these are transformative outcomes.
Who is a good candidate for the PanOptix Pro?
This is where I spend most of the consultation, because the lens is genuinely not right for everyone — and I think it’s important to be honest about that rather than just selling the technology.
The active professional
Uses a computer all day, reads constantly, drives regularly. Wants to function without glasses in virtually all situations.
The presbyopic patient over 50
Increasingly frustrated with reading glasses or varifocals. Has a visually significant cataract or is an appropriate candidate for clear lens extraction.
The refractive lens exchange candidate
Clear lens, high prescription beyond the range for laser surgery, or wanting to eliminate future cataract surgery entirely. Seeking a permanent, once-in-a-lifetime solution.
The glasses-intolerant patient
Has worn glasses all their life and simply wants to be free of them. High motivation, realistic expectations, and willing to adapt through the neuroadaptation period.
Equally important is who I’d steer away from the PanOptix Pro. Patients with significant macular pathology, advanced glaucoma causing contrast sensitivity loss, or occupations demanding the very highest quality night vision — commercial pilots, for example — are generally better served by a monofocal or EDOF lens. The trifocal’s optical magic comes with a small but real trade-off in contrast under difficult conditions, and for some patients that trade-off isn’t acceptable.
I also have a frank conversation about the neuroadaptation period. Most patients experience some degree of halo or glare in the first weeks to months after surgery. The brain is remarkably good at suppressing these — most patients tell me they’ve stopped noticing by the three-month mark — but patients who are intolerant of any visual disturbance during the settling period are not ideal candidates for a multifocal platform.
My personal take
I’ve been implanting trifocal IOLs for a number of years now, and the lens I reach for most often in patients wanting premium outcomes is the PanOptix platform. The Pro iteration builds on a track record I already trusted, and the improvements in the diffractive optics are clinically meaningful rather than cosmetic.
What I find most compelling is the consistency. When a patient sits in my chair at the three-month review and tells me they’ve been skiing, reading restaurant menus, using their phone, and driving at night — all without glasses — that’s the outcome we worked toward together. The PanOptix Pro is delivering that outcome at a rate I’m very comfortable with.
If you’re considering cataract surgery or refractive lens exchange and wondering whether a premium trifocal lens is right for you, I’d encourage you to come in for a consultation. We’ll go through your measurements, your lifestyle, your visual priorities, and be honest about what the lens can and can’t do. Not everyone leaves with the same recommendation — and that’s exactly as it should be.
To book a consultation: (07) 3239 5000 · www.drgeoffreyryan.com.au